EUR/USD likely to find a peak near 1.25: UBS
Chadwick Jeremy G, the Chief Operating Officer of Kymera Therapeutics, Inc. (NASDAQ:KYMR), a biotech company with a market capitalization of $2 billion, recently made significant stock transactions as reported in a Form 4 filing with the SEC. On March 3, 2025, Chadwick sold a total of 1,383 shares of common stock, valued at approximately $42,113. The shares were sold at a weighted average price between $30.33 and $31.00, with the stock currently trading near its 52-week low of $29.16. According to InvestingPro data, the stock has declined about 15% in the past week.
The transactions were executed to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). These sales were automatic and not at the discretion of Chadwick. Following these transactions, Chadwick’s direct ownership of Kymera’s common stock now stands at 67,800 shares. While the company maintains a strong liquidity position with a current ratio of 7.5x and more cash than debt on its balance sheet, InvestingPro analysis reveals 10+ additional key insights about the company’s financial health and valuation.
Additionally, Chadwick acquired 25,000 RSUs and 50,000 stock options, both with no immediate cash transaction. The RSUs are set to vest in three equal annual installments starting March 3, 2025, while the stock options will vest monthly over three years, contingent upon continued employment. For comprehensive insider trading analysis and detailed financial metrics, investors can access Kymera’s complete Pro Research Report, available exclusively on InvestingPro.
In other recent news, Kymera Therapeutics reported fourth-quarter 2024 financial results that did not meet analyst expectations. The company posted a loss of $0.88 per share, exceeding the predicted loss of $0.77 per share, and revenue was $7.39 million, falling short of the anticipated $14.71 million. Revenue from collaborations declined significantly year-over-year, attributed entirely to its partnership with Sanofi (NASDAQ:SNY). Despite these results, Kymera maintains a strong financial position with $851 million in cash, which is expected to sustain operations until mid-2027. In analyst updates, Truist Securities reaffirmed a Buy rating with a $53 price target, expressing confidence in the company’s ongoing programs. Meanwhile, H.C. Wainwright adjusted the price target to $54 from $60, maintaining a Buy rating, reflecting cautious optimism about Kymera’s clinical trials. The company has also announced a new performance-based stock unit plan to align employee incentives with clinical success. These developments highlight Kymera’s strategic focus on advancing its clinical programs and achieving key milestones.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.